ArticleFrontiers in pharmacology2026
Efficacy and safety of topical human keratinocyte growth factor-2 for dry eye disease: evidence from
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to assess the therapeutic efficacy and safety pharmacology of human keratinocyte growth factor-2 (hKGF-2) eye drops for dry eye disease (DED). Methods: We assessed the primary pharmacodynamics of hKGF-2 in two animal models of DED: the benzalkonium chloride (BAC)-induced rabbit model and the scopolamine (SCOP)-induced rat model. Three different doses of hKGF-2 eye drops were administered topically and compared with two commercially available medicines as positive controls, including sodium hyaluronate (SH) eye drops and bovine basic fibroblast growth factor (bFGF) eye drops. The primary endpoints included tear secretion measurement, corneal fluorescein staining (CFS), tear film break-up time (TBUT), and histopathologic examination. For the safety pharmacology studies, the effects on the central nervous system (CNS) were determined using the functional observation battery (FOB) in rats. Additionally, the impacts on the cardiovascular and respiratory systems were analyzed in Beagle dogs by monitoring electrocardiogram (ECG), respiration (RESP), and blood pressure (BP). Results: Following 21 days of treatment, all topical hKGF-2 dosage groups (50, 100, 200 μg/mL) showed significant therapeutic effects, which were as effective as the bFGF and SH eye drops. The minimum effective dose (MED) of hKGF-2 in this study was 50 μg/mL. These therapeutic benefits included enhancing basal tear secretion and tear film stability, mitigating corneal damage, and promoting the recovery of corneal thickness as well as the restoration of conjunctival goblet cell counts. In safety pharmacology assessments, FOB results demonstrated that hKGF-2 treatment (20, 50, 100 μg per animal) had no adverse effects on the CNS of rats. Meanwhile, topical administration of hKGF-2 (160, 400, 800 μg per dog) did not elicit any adverse reactions in the cardiovascular or respiratory systems of beagles. Conclusion: Topical administration of hKGF-2 effectively ameliorated DED symptoms without adverse effects on the CNS, cardiovascular, and respiratory systems. These results indicated that hKGF-2 eye drops have potential as a safe and effective treatment for DED, and provided reliable preclinical evidence for its subsequent clinical trials and translational application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.